By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem bringing manufacturing and scientific insights to TIDES USA
Bubendorf, Switzerland: –Bachem AG will again be prominent as a scientific contributor and leading exhibitor at the prestigious TIDES USA conference, this time in San Diego, California.
Bachem is a regular supporter of the TIDES meetings, which form of the pharma industry’s largest and most renowned events dedicated to accelerating peptide and oligomer-based therapeutics to market, focusing on strategies for expediting R&D and improving CMC efficiency.
Bachem will contribute three presentations to the scientific program, starting with an opening day workshop presentation from its Vice President for CMC Development, Matteo Villain, on ‘Mutagenic and Genotoxic Substance Control In Peptides: ICH M7 As A Guidance In the Evaluation of Peptidic APIs’ (Sunday, May 7, 1545pm – 1615 hrs).
The following day, Senior Director for Oligo R&D, Dr. Arne Berthelmann will deliver a lunchtime presentation on ‘New Oligonucleotide SPOs Protocol With Stirred Bed Technology’ (Monday, May 8, 1205-1235 hrs).
On the closing day, Bachem VP for Peptide Manufacturing, Dr. Stefan Eissler, will present the Peptide Track with his insights on ‘Larger Quantities, Ever More Complex Peptides, Environmental Footprint: New Challenges Facilitate A Turning Point In Peptide Manufacturing’ (Wednesday, May 10, 1045-1115 hrs).
Bachem will also be part of the Exhibition Zone at the Manchester Grand Hyatt, San Diego, with its stand at Booth 311 showcasing its advanced technologies and expanding portfolio of CMO capabilities in oligonucleotides, supplementing its long-established leadership in peptide-based therapies and new chemical entities (NCEs). On Tuesday May 10, the Bachem stand will be serving free popcorn and on the final day will host events including a Quiz and Drawing Competition.
The Bachem team at TIDES USA 2023 will be led by CCO Torsten Woehr, supported by Vice President ＆ Head, Global Business Development, Chris McGee, Senior Business Development Manager Joe Fraone, and Business Development Managers, Noah Duffy, Federica Decò, and Keith Porter.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
About TIDES USA 2023
The TIDES USA Oligonucleotide and Peptide Therapeutics conference is billed as the pharma industry’s largest event focused on accelerating peptide-based therapeutics to market, featuring leading strategies for expediting R&D and improving CMC efficiency
This annual conference’s scientific agenda includes more than 150 speakers, including the industry’s leading scientists, presenting latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC, Manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products.
TIDES USA 2023 is a four day event, opening May 7 at the Manchester Grand Hyatt in San Diego CA, with a parallel digital platform.
The 2023 conference will feature parallel discussion tracks covering six scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing.
The event is organized by Informa Connect, with further information at: https://informaconnect.com/tides/